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Abstract
Background: Genetically engineered neural stem cell (NSC) lines are promising vectors for the
treatment of neurodegenerative diseases, particularly Parkinson's disease (PD). Neurturin (NTN),
a member of the glial cell line-derived neurotrophic factor (GDNF) family, has been demonstrated
to act specifically on mesencephalic dopaminergic neurons, suggesting its therapeutic potential for
PD. In our previous work, we demonstrated that NTN-overexpressing c17.2 NSCs exerted
dopaminergic neuroprotection in a rat model of PD. In this study, we transplanted NTN-c17.2 into
the striatum of the 6-hydroxydopamine (6-OHDA) PD model to further determine the
regenerative effect of NTN-c17.2 on the rat models of PD.
Results: After intrastriatal grafting, NTN-c17.2 cells differentiated and gradually downregulated
nestin expression, while the grafts stably overexpressed NTN. Further, an observation of
rotational behavior and the contents of neurotransmitters tested by high-performance liquid
chromatography showed that the regenerative effect of the NTN-c17.2 group was significantly
better than that of the Mock-c17.2 group, and the regenerative effect of the Mock-c17.2 group was
better than that of the PBS group. Further research through reverse-transcriptase polymerase
chain reaction assays and in vivo histology revealed that the regenerative effect of Mock-c17.2 and
NTN-c17.2 cell grafts may be attributed to the ability of NSCs to produce neurotrophic factors
and differentiate into tyrosine hydroxylase-positive cells.
Conclusion: The transplantation of NTN-c17.2 can exert neuroregenerative effects in the rat
model of PD, and the delivery of NTN by NSCs may constitute a very useful strategy in the
treatment of PD.
Background
A pathologic feature of Parkinson's disease (PD) is the loss
of melanized dopaminergic neurons within the substantia
nigra (SN) pars compacta coupled with depletion of stri-
atal dopamine. This is responsible for the major motor
features of the disease [1]. Current symptomatic treat-
ments involving dopaminergic replacement therapy and
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deep brain stimulation (DBS) therapy cannot prevent fur-
ther neurodegeneration and disease progression [2,3].
In recent years, researchers have searched for preventative
and curative strategies, leading to the development of cer-
tain novel therapeutic approaches. Most of these
approaches are based on strategies of neuroprotection,
whereby dopaminergic neurons are prevented from
dying, and neuroregeneration, whereby dead or injured
neurons are supplemented by transplantation [4-7].
Neurturin (NTN) is a member of the glial cell line-derived
neurotrophic factor (GDNF) family of neurotrophic fac-
tors. NTN acts on dopaminergic neurons through a recep-
tor complex composed of ligand-binding subunits and
GDNF family receptors a-1 (GFR a-1) and a-2 (GFR a-2)
[8,9]. The neuroprotective and neuroregenerative effects
of NTN are equipotent to GDNF when tested on develop-
ing ventral mesencephalic dopamine (DA) neurons cul-
tured in vitro [10] as well as on damaged nigrostriatal DA
neurons in vivo [11]. Based on the neuroprotective effects
on nigrostriatal DA neurons, NTN has been suggested as a
candidate for the treatment of PD.
Recently, we cloned the prepro-NTN cDNA and inserted it
into the pcDNA3.1-hygro-NTN plasmid for introduction
into a stable NSC line (c17.2) [12]. We have demon-
strated that NTN-expressing c17.2 neural stem cells
(NSCs) exerted dopaminergic neuroprotection in a rat
model of PD [13]. In this study, we transplanted NTN-
c17.2 into the striatum of the 6-hydroxydopamine (6-
OHDA) model of PD to further determine the regenera-
tive effect of NTN-c17.2 on the rat models of PD.
Results
Engineering and characterization of NTN expression in 
NSCs
The c17.2 mouse NSCs were transfected with the
pcDNA3.1-Hygro-NTN vector to generate NTN-c17.2 cells
or the pcDNA3.1-Hygro vector to generate Mock-c17.2
cells. The amount of NTN mRNA and secreted NTN pro-
tein in the culture medium were detected by northern and
western blots, respectively. Clone 1, the highest expressor,
was named NTN-c17.2, and detailed characterization of
NTN-c17.2 was described elsewhere [13].
Detection of NTN protein expression in NSCs after 
intrastriatal grafting in vivo
NTN and nestin protein-expressing cells of the corpus
striatum were identified by immunohistochemistry 4.5,
30, and 120 d after the animals were transplanted with
NTN-c17.2 cells (Fig. 1A–F). A large number of cells
expressing NTN and nestin protein were detected at 4.5 d
(Fig. 1D). The majority of cells were round and not differ-
entiated. The cells differentiated 30 days after transplanta-
tion (Fig. 1E) but only expressed the NTN protein, while
the number of cells declined. A small number of NTN-
positive cells were still detected 120 d postgrafting (Fig.
1F).
NTN-c17.2 cells efficiently prevent the loss of nigral 
dopaminergic neurons in a rat model of PD
In our study, tyrosine hydroxylase (TH) immunohisto-
chemistry demonstrated comparable 40% or 36% loss of
nigral dopaminergic neurons in animals injected with PBS
plus 6-OHDA or Mock-c17.2 plus 6-OHDA, respectively
(Fig. 2C,D,E). In contrast, only a 16% loss of nigral
In the neuroregeneration study, the engrafted NTN-c17.2  cells survived the grafting procedure well and expressed high  levels of the NTN protein in vivo Figure 1
In the neuroregeneration study, the engrafted NTN-c17.2 
cells survived the grafting procedure well and expressed high 
levels of the NTN protein in vivo. A-F, Double immunohisto-
chemistry with anti-β-Gal (LacZ, in red) or NTN (red) anti-
body (no crossreaction with GDNF) and anti-Nestin (green) 
showed cells expressing the NTN protein in the NTN-c17.2 
engrafted striatum 4.5 d, 30 d and 120 d postgrafting; how-
ever, with time, the cells differentiated, and the number of 
cells declined and almost no nestin protein was detected 30 
d and 120 d postgrafting. G, Quantification of the number of 
LacZ+ Nestin+, and NTN+ Nestin+ cells. The number of 
immune-positive cells were counted in 7 serial sections 
through the striatum. Values represent the mean ± SEM. *#P 
< 0.01. The striatum grafted with NTN-c17.2 or Mock-c17.2 
cells at 4.5 d were compared with 30 d and 120 d postgraft-
ing, which was determined by one-way ANOVA. Scale bars: 
250 µm.Molecular Neurodegeneration 2007, 2:19 http://www.molecularneurodegeneration.com/content/2/1/19
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dopaminergic neurons was measured in animals grafted
with the NTN-c17.2 NSCs (P < 0.05) (Fig. 2B,E). These
results suggest that the grafts of NTN-c17.2 cells in the cor-
pus striatum could protect the TH-positive neurons of the
ipsilateral SN from 6-OHDA insult.
Behavior observation
Intrastriatal grafting of NTN-c17.2 and Mock-c17.2 
improves behavioral abnormalities
We observed the ethology of experimentally grafted rats
for up to 10 months to determine whether NTN-c17.2
cells had a regenerative effect on animal behavioral abnor-
malities (Fig. 3). The behavioral asymmetry in the NTN-
c17.2 group was improved at almost all time points tested
as compared with the PBS and Mock-c17.2 groups. A sig-
nificant statistical difference was noted between the NTN-
c17.2 group and PBS group from 2 months to 10 months.
Behavioral improvement was also observed from 3
months to 10 months among the NTN-c17.2 and Mock-
c17.2 groups. Otherwise, the behavioral asymmetry was
greatly improved in the Mock-c17.2 group than in the PBS
group from 4 months to 10 months following grafting.
NTN-c17.2 and Mock-c17.2 NSCs exert regenerative 
effects assayed by high- performance liquid 
chromatography
Ten months after the ethological observation, the animals
were sacrificed and examined for the measurement of DA,
3,4-dihydroxyphenylacetic acid (DOPAC), and homova-
nillic acid (HVA) levels by high-performance liquid chro-
matography (HPLC) (Fig. 4). The contents of DA,
In the neuroregeneration study, the NTN-c17.2 and Mock- c17.2 cells survived after transplantation and ameliorated the  apomorphine-induced rotational behavior in the rat model of  PD Figure 3
In the neuroregeneration study, the NTN-c17.2 and Mock-
c17.2 cells survived after transplantation and ameliorated the 
apomorphine-induced rotational behavior in the rat model of 
PD. The rat model of 6-OHDA-induced hemiparkinsonism 
was selected and grafting was performed. Apomorphine-
induced circling behavior was tested every month for 10 
months after transplantation. From 2 to 10 months, the rats 
engrafted with NTN-c17.2 cells showed fewer rotations than 
those injected with Mock-c17.2 cells (#P < 0.05) or PBS (*P < 
0.05). From 4 to 10 months, rats engrafted with Mock-c17.2 
showed fewer rotations as compared with those injected 
with PBS (*P < 0.05).
In the neuroprotection study, NTN-c17.2 grafts protected  SN dopaminergic neurons in a 6-OHDA model of PD Figure 2
In the neuroprotection study, NTN-c17.2 grafts protected 
SN dopaminergic neurons in a 6-OHDA model of PD. A-D, 
TH immunohistochemistry showed the grafting of NTN-
c17.2 cells (B) prevented the loss of dopaminergic neurons in 
the SN, while the grafts of Mock-c17.2 cells (C) and treat-
ment with PBS (D) could not prevent the loss of dopaminer-
gic neurons. E, Quantification of the number of TH-positive 
neurons in SN under the indicated experimental conditions. 
The number of TH-positive cells was counted in 7 serial sec-
tions of the SN. Values represent the mean ± SEM (n = 5). 
*#P < 0.05. The lesioned SN grafted with NTN-c17.2 cells 
was compared with samples from animals grafted with Mock-
c17.2 cells or injected with PBS, as determined by one-way 
ANOVA (significant effect of treatment, p < 0.05). Scale bars: 
(in D) A-D, 250 µm.Molecular Neurodegeneration 2007, 2:19 http://www.molecularneurodegeneration.com/content/2/1/19
Page 4 of 7
(page number not for citation purposes)
DOPAC, and HVA in the corpus striatum were 35%, 42%,
and 39%, respectively, in the PBS group; 67% (P < 0.05),
77% (P < 0.05), and 73% (P < 0.05), respectively, in the
NTN-c17.2 group; and 52% (P < 0.05), 51%, and 65%,
respectively, in the Mock-c17.2 group. Taken together,
these results showed that the NTN-c17.2 and Mock-c17.2
groups recovered significantly during the latter period of
the transplantation study as compared with the PBS
group, and the NTN-c17.2 group recovered better than the
Mock-c17.2 group.
NSCs expressing c17.2 and their derivatives constitutively 
secrete neurotrophic factors and partially differentiate 
into TH-positive cells
To further determine the regenerative effect of NTN-c17.2
and Mock-c17.2 transplantation on 6-OHDA-induced
Parkinsonism in rats, we first performed a double immun-
ofluorescence assay to test whether NTN-c17.2 and Mock-
c17.2 cells transplanted in the corpus striatum could dif-
ferentiate into TH-positive cells. Simultaneously, c17.2
cells were transplanted into the corpus striatum. We
found that only a few cells differentiated into TH-positive
cells (<10%) (Fig. 5A–I), and no significant statistical dif-
ference was noted in the number of cells among NTN-
c17.2, Mock-c17.2, and c17.2. Secondly, we used reverse-
transcriptase polymerase chain reaction (RT-PCR) to spe-
cifically test Mock-c17.2 and NTN-c17.2 for the expres-
sion of the mouse-derived neurotrophic factors GDNF,
brain-derived neurotrophic factor (BDNF) (Fig. 5J), nerve
growth factor (NGF), and NTN in the transplanted corpus
striatum. We identified the expression of these neuro-
trophic factors in vitro and in vivo. Thus, the regenerative
effect of Mock-c17.2 transplantation on the rat PD model
may be due, at least in part, to both palliative differentia-
tion and expression of neurotrophic factors, while this
effect could be strengthened by NTN-c17.2 transplanta-
tion.
In the neuroregeneration study, it is possible that the  observed neuroregenerative effect from intrastriatal grafting  with NTN-c17.2 and Mock-c17.2 cells may be due to partial  differentiation of cells into TH-positive cells and the expres- sion of neurotrophic factors by NSCs in vivo Figure 5
In the neuroregeneration study, it is possible that the 
observed neuroregenerative effect from intrastriatal grafting 
with NTN-c17.2 and Mock-c17.2 cells may be due to partial 
differentiation of cells into TH-positive cells and the expres-
sion of neurotrophic factors by NSCs in vivo. A-I, Double 
immunohistochemistry of TH (B, E, H), LacZ (A, D), and 
NTN(G) revealed that some grafted c17.2, NTN-c17.2, and 
Mock-c17.2 cells could differentiate into TH-positive cells 30 
d postgrafting. J, Nonquantitative RT-PCR of neurotrophic 
factor genes using mouse-specific primers (mouse-specific) 
demonstrated the expression of these genes in Mock-c17.2 
(lane 1), NTN-c17.2 cells (lane 4), rat striatum grafted with 
Mock-c17.2 cells (lane 2), and NTN-c17.2 cells (lane 5) (30 d 
after grafting), but this expression was not observed after 
RT-PCR of the cDNA of control rat cerebrum (lane 3). The 
endogenous control β-actin was amplified using mouse-spe-
cific primers in lanes 1, 2, 4, and 5 with rat-specific primers in 
lane 3.
DA, DOPAC, and HVA concentrations (mean ± SEM) in the  striatum as measured by HPLC with electrochemical detec- tion Figure 4
DA, DOPAC, and HVA concentrations (mean ± SEM) in the 
striatum as measured by HPLC with electrochemical detec-
tion.Molecular Neurodegeneration 2007, 2:19 http://www.molecularneurodegeneration.com/content/2/1/19
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Discussion
Neuroprotective therapy involves postponing or retarding
the development of a neurodegenerative disease by inhib-
iting its pathogenic factors. The exact pathogenesis of PD
is not fully understood, and there is no evidence that PD
is linked to deficiencies in GDNF and other neurotrophic
factors. However, experimental data have shown that oxi-
dative stress, mitochondrial dysfunction, and calcium
overload induced by internal and external toxins are asso-
ciated with the pathogenesis of PD [14-17]. Similar to
GDNF, NTN not only can promote the development and
function of dopaminergic neurons but also has neuropro-
tective and regenerative effects on dopaminergic neurons
injured by neurotoxins such as 6-OHDA, 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP) and methyl
amphetamine [11,18].
In our previous experiment, we transplanted an NTN-
secreting c17.2 NSC line into the striatum of a 6-OHDA
PD model and found that the inverse transfer of the NTN
protein into the SN protected dopaminergic neurons from
6-OHDA toxicity. The observation of rotational behavior
showed that the improvement in the NTN group was
obvious compared with that in the Mock group (data not
shown). Only NTN-c17.2 NSCs demonstrated their neu-
roprotective effects.
To further investigate the therapeutic effects of NTN on a
6-OHDA-induced hemiparkinsonian rat model, we trans-
planted the various NSC cells into the corpus striatum of
the model animals and measured their rotational activity
in response to apomorphine. We know that the rat model
of PD induced by 6-OHDA has a tendency of gradual
recovery, which was also observed in our research. After 4
months, the number of rotations in the PBS group
decreased gradually. However, the overall number of rota-
tions demonstrated the following order: NTN group <
Mock group < PBS group. After 4 months, the NTN and
Mock groups showed a similar number of rotations,
which was clearly lower than those in the PBS group. The
difference between the NTN and Mock groups was statis-
tically significant from 4 to 10 months. Since the model
was established by administering 6-OHDA injections into
the ventral tegmental area (VTA) and the medial forebrain
bundle (MFB), the dopaminergic neurons in the SN and
the nigrostriatal dopaminergic pathway were both dam-
aged. Thus, our previous results are explained by the fact
that while the NTN protein protects against 6-OHDA tox-
icity and the resultant inflammatory process, it cannot
increase the total number of dopaminergic neurons after
the SN is destroyed. We thought that the transplanted
NSC cells combined with the host cells in the striatum and
improved the symptoms in a hemiparkinsonian rat model
4 months post-transplantation. Further, the study of rota-
tional behavior and DA and its metabolites in the thera-
peutic study supported this conclusion [19].
Yang et al [20] found that after the c17.2 clonal lines were
transplanted into the intact striatum or striatum bearing
6-OHDA-induced lesions, the majority of cells spontane-
ously expressed the DA biosynthetic enzymes, TH, and
aromatic L-amino acid decarboxylase. Further study [21]
showed that all the engrafted cells in 65% of the grafts that
were obtained only from high confluence cultures and
maintained for 12–20 passages expressed TH but not the
markers of other neurotransmitter systems. However, in
our study, c17.2 was transfected with NTN and Mock,
which ranged from 5 to 9 passages and was not passaged
at a comparably high confluence. We have shown that
NTN-c17.2 and Mock-c17.2 NSCs can differentiate only
partially into TH-positive neurons, not as many as
observed by Yang. There was no obvious difference in cell
numbers between NTN-c17.2 and Mock-c17.2 NSCs (data
not shown). These TH-positive neurons and other differ-
entiated cells from transplanted cells improved the symp-
toms of the hemiparkinsonian rat model.
The present RT-PCR experiment revealed that the mRNAs
for GDNF, BDNF, and NGF were expressed in NTN-c17.2
and Mock-c17.2 NSCs both in vitro and in vivo. This is
consistent with the findings of Lu et al [22] who reported
that NSCs constitutively secreted neurotrophic factors.
Although the concentrations of these neurotrophic factors
are not as high as NTN from NTN-c17.2, their regenerative
effects are potent. Thus, NSCs can not only differentiate
into distinct cells of the nervous system but also promote
the repair of the nervous system by secreting neurotrophic
factors. Hence, the regenerative effect of NSC grafts may
be related to these 2 factors, while the NTN-c17.2 cell
grafts may reinforce the therapeutic effect through high
expression of NTN.
Conclusion
The transplantation of NTN-c17.2 exerted neuroregenera-
tive effects in the rat model of PD. The regenerative effect
of NSC grafts may be related to these 2 factors: NSCs can
differentiate into distinct cells of the nervous system and
constitutively secrete neurotrophic factors, while the
NTN-c17.2 cell grafts may reinforce the therapeutic effect
through high expression of NTN.
Materials and methods
Cell culture
c17.2 NSCs and their derivatives were grown in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum, 5% horse serum, 100 mg/L
ampicillin, and 100 mg/L streptomycin (all obtained
from Life Technologies, Grand Island, NY) at 37°C under
a 5% CO2 atmosphere and passaged as described previ-Molecular Neurodegeneration 2007, 2:19 http://www.molecularneurodegeneration.com/content/2/1/19
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ously [12]. The differentiating cells were grown in an N2
medium consisting of a 1:1 mixture of F12 and DMEM
with 1% N2. c17.2 NSCs contained the autonomous
genetic marker LacZ in the cell. c17.2 transfected with
NTN and Mock was named passage 1. The cells were pas-
saged at 90% confluence. The cells from 5 to 9 passages
were collected for transplantation.
Construction of the NTN-c17.2 cell line
A cDNA fragment encoding prepro-NTN was amplified by
RT-PCR using total RNA from mouse testis. The cDNA was
further subcloned into pcDNA3.1-Hygro plasmids, which
were transfected into c17.2 cells using the Lipofectamine
(LF) 2000 reagent (Life Technologies). Briefly, according
to the manufacturer's instructions, logarithmically grow-
ing cells were transfected with 1 µg of plasmids and 2 µl
of LF2000 reagent. At 72 h after transfection, the selective
medium containing 1 mg/ml of the antibiotic hygromy-
cin (Life Technologies) was selected. Two weeks later, 5
colonies were picked, propagated, and characterized for
mRNA and protein expression. The mRNA assay was
detected by northern blot, and protein expression was
detected by western blot. The detailed process is described
in our previous work [13].
Study design
Young adult male Sprague-Dawley rats (Sino-British
Sippr/Bk Lab Animal Ltd., Shanghai, China), weighing
180–210 g at the beginning of this experiment, were
housed under a 12-h light/12-h dark cycle with free access
to food and water. All the experiments were approved by
the local ethics committee.
A total of 90 male Sprague-Dawley rats were used for the
neuroprotection and regeneration studies, as shown in
Table 1. For the neuroprotection study, NTN-c17.2, Mock-
c17.2, and PBS were injected into the striatum, and striatal
lesions were induced using 6-OHDA on the same side
after 15 d [13]. In the neuroregeneration study, 16 µg of
6-OHDA was stereostatically injected into MFB and VTA
at the following coordinates (in millimeters) with an inci-
sor bar at -2.4: anteroposterior (AP)(bregma), -3.7; lateral
(L), 1.7; dorsoventral (DV), -7.8; and AP (bregma), -4.8;
L, 1.0; DV, -7.8, respectively. Four weeks post-injection,
45 animals showing rotational behavior of over 7 turns/
min in response to 0.5 mg/kg of apomorphine (Sigma)
were selected for neuroregeneration study of NTN. Prolif-
erative state Mock-c17.2 and NTN-c17.2 cells were
washed twice with serum-free DMEM, detached with a cell
lifter (Costar, Cambridge, MA), dissociated with a fire-
polished Pasteur pipette, pelleted, and resuspended at a
concentration of 50,000 cells/µl. A total of 600,000 cells
were injected into 6 locations at the following coordinates
(in millimeters) with the incisor bar at 0: AP (bregma),
1.0; L, 3.0; DV (dura), -4.5 and -5.0; AP (bregma), -0.1; L,
3.7; DV (dura), -4.5 and -5.0; and AP (bregma), -1.2; L,
4.5; DV (dura), -4.5 and -5.0. Every month post-trans-
plantation, the animals (n = 15 in each group) were tested
for similar rotational behavior at different time points,
and biochemical measurements were carried out at the
end of the experiments.
Histology
Rats were sacrificed and transcardially perfused with 4%
paraformaldehyde. Serial cryostat sections (15 µm thick)
of the striatum were obtained. The specific cell-type mark-
ers used were anti-nestin for NSCs (1:1000; Chemicon,
Temecula, CA), anti-NTN for the NTN protein (1:400;
Santa Cruz), anti-TH for dopaminergic neurons, and anti-
β-Gal for c17.2 or Mock-c17.2 cells (1:1000; Chemicon).
The appropriate secondary antibodies were horse anti-
mouse fluorescein isothiocyanate-conjugated antibody
(1:100; Vector Laboratories, Burlingame, CA), horse anti-
mouse Texas Red (1:100; Vector), or rabbit anti-goat fluo-
rescein (1:100; Vector). Double immunostaining of the
sections was performed by simultaneous incubation of
the sections with the appropriate pairs of primary and sec-
ondary antibodies. The number of LacZ+ Nestin+, NTN+
Nestin+, or TH+ cells were counted in the striatum by using
an optical fractionator method for unbiased stereological
cell counting [23]. The stained slides were examined using
a Zeiss microscope (Oberkochen, Germany).
Table 1: Experimental design of the neuroprotection and regeneration study
Protection Study NTN (n = 15)
Mock (n = 15)
PBS (n = 15)
15 days 6-OHDA lesion 4.5 days or every month
(n = 15 in each group)
Rotation behavior 
and Sacrifice for IHC, 
HPLC
Regeneration 
Study
6-OHDA lesion (n = 45) 4 weeks Rotation Behavior NTN (n = 15)
Mock (n = 15)
PBS (n = 15)
every month
(n = 15 in each group)
Rotation behavior 
and Sacrifice for IHC, 
HPLC
NTN-c17.2, Mock- c17.2, and PBS were transplanted into the striatum by the conventional microinjection method. Subsequently, 6-
hydroxydopamine (6-OHDA) was infused into the striatum or into the medial forebrain bundle (MFB) and the ventral tegmental area (VTA) in the 
neuroprotection study or regeneration study, respectively (see Materials and Methods). After transplantation, all the animals were analyzed for 
apomorphine-induced rotational behavior and then sacrificed for immunohistochemistry (IHC) and high-performance liquid chromatography 
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RT-PCR for in vitro and in vivo measurements of growth 
factor mRNA expression
Total RNA was isolated from undifferentiated cultured
NTN-c17.2 and Mock-c17.2 NSCs, grafted NTN-c17.2 and
Mock-c17.2, and contralateral cerebrum (30 d after graft-
ing) using the Trizol reagent. First-strand cDNA was syn-
thesized from 2 µg total RNA using the Reverse
Transcription System for RT-PCR Kit (Promega, USA) with
oligo (dT) priming, according to the manufacturer's
instructions. In order to specifically detect the gene expres-
sion of mouse NSC-derived growth factor, mouse-specific
primers with at least one 3' end nucleotide mismatch to
the rat genes were designed for the genes of the neuro-
trophic factors NGF, BDNF, GDNF [22], and NTN based
on BLAST comparison of the mouse and rat genes. The
mouse and rat β-actin genes were amplified to serve as a
normalization control.
Statistical analysis
All data were expressed as mean ± SEM and analyzed
using SPSS statistical software. The changes in turning
behavior were analyzed using one-way ANOVA with
repeated measures for time. Statistical significance was
defined as P < 0.05.
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